You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: March 14, 2025

Claims for Patent: 11,542,239


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 11,542,239
Title:Elagolix sodium compositions and processes
Abstract:The present invention relates to compositions of elagolix sodium, and process and intermediates for the preparation thereof.
Inventor(s):Niharika Chauhan, Raimundo HO, Albert Kruger, Samrat MUKHERJEE, Stephen T. Chau, Erika Crane, Alex Fabian, Sanjay Chemburkar, Travis Dunn
Assignee:AbbVie Inc
Application Number:US16/519,443
Patent Claims: 1. A composition comprising: Compound (I), and one or more impurity selected from a group consisting of: wherein Compound (I) comprises at least 97 weight percent of the composition and wherein the one or more impurity is present in an amount that is greater than zero and equal to or less than 3 weight percent of the composition.

2. The composition of claim 1, wherein the composition further comprises one or more additional impurities, wherein the one or more additional impurities are selected from the group consisting of:

3. The composition of claim 1, wherein Compound (I) is substantially amorphous.

4. The composition of claim 1, wherein the composition comprises at least 98 weight percent Compound (I) and wherein the one or more impurity is present in an amount that is greater than zero and equal to or less than 2 weight percent of the composition.

5. A composition comprising, Compound (I), and one or more impurity selected from a group consisting of: wherein the composition comprises at least about 97 weight percent of Compound (I), and wherein the one or more impurity is present in an amount that is greater than zero and equal to or less than 3 weight percent of the composition, and further wherein the composition is prepared by a process comprising, using as an intermediate, Compound (II),

6. The composition of claim 5, wherein the process further comprises reacting Compound (IIa), with salicylic acid to form Compound (II).

7. The composition of claim 6, wherein the process further comprises isolating Compound (II) to provide an isolated Compound (II).

8. The composition of claim 5, wherein the composition further comprises one or more additional impurities, wherein the one or more additional impurities are selected from the group consisting of:

9. A composition comprising: Compound (I) and one or more impurity selected from a group consisting of: ethyl 4-[(4R)-2-oxo-4-phenyl-1,2λ4,3-oxathiazolidin-3-yl]butanoate; ethyl 4-[(4R)-2,2-dioxo-4-phenyl-1,2λ6,3-oxathiazolidin-3-yl]butanoate; and (4-ethoxy-4-oxobutyl){(1R)-2-[5-(2-fluoro-3-methoxyphenyl)-3-{[2-fluoro-6-(trifluoromethyl)phenyl]methyl}-4-methyl-2,6-dioxo-3,6-dihydropyrimidin-1-(2H)-yl]-1-phenylethyl}sulfamic acid or a salt thereof, wherein the composition comprises at least about 97 weight percent of Compound (I); and wherein the one or more impurity is present in an amount that is greater than zero and equal to or less than 3 weight percent of the composition, and further wherein the composition is prepared by a process comprising, using as an intermediate, Compound (VIa),

10. The composition of claim 9, wherein the composition further comprises one or more additional impurities, wherein the one or more additional impurities are selected from the group consisting of:

11. A composition comprising, Compound (I), and one or more impurity a second compound selected from a group consisting of: wherein the composition comprises at least about 97 weight percent of Compound (I) and wherein the one or more impurity is present in an amount that is greater than zero and equal to or less than 3 weight percent of the composition.

12. The composition of claim 1, wherein the composition further comprises one additional impurity, wherein the one additional impurity is:

13. The composition of claim 5, wherein the composition further comprises one additional impurity, wherein the one additional impurity is:

14. The composition of claim 9, wherein the composition further comprises one additional impurity, wherein the one additional impurity is:

15. The composition of claim 1, wherein the one or more impurity comprises Compound (iii) the composition comprises at least 97 weight percent of Compound (I) and not more than 0.25 weight percent Compound (iii).

16. The composition of claim 1, wherein the one or more impurity comprises Compound (v) the composition comprises at least 97 weight percent of Compound (I) and not more than 0.55 weight percent Compound (v).

17. The composition of claim 1, wherein the one or more impurity comprises Compound (vi) the composition comprises at least 97 weight percent of Compound (I) and not more than 0.40 weight percent Compound (vi).

18. The composition of claim 1, wherein the one or more impurity comprises Compound (vii) the composition comprises at least 97 weight percent of Compound (I) and not more than 0.35 weight percent Compound (vii).

19. The composition of claim 11, wherein the one or more impurity comprises Compound (x) the composition comprises at least 97 weight percent of Compound (I) and not more than 25 parts per million (ppm) Compound (x).

20. The composition of claim 11, wherein the one or more impurity comprises Compound (xv) the composition comprises at least 97 weight percent of Compound (I) and not more than 0.6 parts per million (ppm) Compound (xv).

21. The composition of claim 11, wherein the one or more impurity comprises Compound (xvi) the composition comprises at least 97 weight percent of Compound (I) and not more than 0.9 parts per million (ppm) Compound (xvi).

22. The composition of claim 11, wherein the one or more impurity comprises Compound (xvii) the composition comprises at least 97 weight percent of Compound (I) and not more than 2.5 parts per million (ppm) Compound (xvii).

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.